259 related articles for article (PubMed ID: 7469203)
1. Relationship between nuclear DNA distribution and estrogen receptors in human mammary carcinomas.
Auer GU; Caspersson TO; Gustafsson SA; Humla SA; Ljung BM; Nordenskjöld BA; Silfverswärd C; Wallgren AS
Anal Quant Cytol; 1980 Dec; 2(4):280-4. PubMed ID: 7469203
[TBL] [Abstract][Full Text] [Related]
2. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
[TBL] [Abstract][Full Text] [Related]
3. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of nuclear DNA content of laryngeal carcinoma and determination of estrogen receptor (ER) level in laryngeal cancer cells].
Lin S
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990; 25(6):331-3, 382. PubMed ID: 2093343
[TBL] [Abstract][Full Text] [Related]
5. Cytophotometric measurements of nuclear DNA content values in human breast lesions.
Enchev VG; Dobreva PV
Arch Geschwulstforsch; 1987; 57(1):31-7. PubMed ID: 3566463
[TBL] [Abstract][Full Text] [Related]
6. The significance of quantitative biological cell parameters in the handling of mammary carcinoma.
Theve NO; Azavedo E; Blomstedt B; Wiking N; Auer GU
Acta Chir Scand; 1982; 148(3):239-41. PubMed ID: 6291293
[TBL] [Abstract][Full Text] [Related]
7. Ploidy, proliferative activity and estrogen receptor content in human breast cancer.
Raber MN; Barlogie B; Latreille J; Bedrossian C; Fritsche H; Blumenschein G
Cytometry; 1982 Jul; 3(1):36-41. PubMed ID: 7117052
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. [Relation between estrogen receptors and the clinical morphological characteristics of primary breast cancer].
Vishniakova VV; Ermilova VD; Murav'eva NI; Bassalyk LS
Arkh Patol; 1981; 43(7):20-3. PubMed ID: 7271502
[TBL] [Abstract][Full Text] [Related]
11. [Contents of nuclear Feulgen-DNA in carcinoma of the breast. Cytophotometric analysis].
Ricevuti G; Barni S
Arch Sci Med (Torino); 1983; 140(4):393-400. PubMed ID: 6201153
[TBL] [Abstract][Full Text] [Related]
12. Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer.
Nativ O; Umehara T; Colvard DS; Therneau TM; Farrow GM; Spelsberg TC; Lieber MM
Eur Urol; 1997; 32(1):96-9. PubMed ID: 9266239
[TBL] [Abstract][Full Text] [Related]
13. Assessment and significance of diploid-range epithelial populations in DNA aneuploid breast carcinomas using multi-parametric flow cytometry.
Visscher DW; Sochacki P; Ottosen S; Wykes S; Crissman JD
Anal Cell Pathol; 1995 Jun; 8(4):267-77. PubMed ID: 7577742
[TBL] [Abstract][Full Text] [Related]
14. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
[TBL] [Abstract][Full Text] [Related]
15. [Study of DNA content using a flow cytometry method and steroid hormone receptors in breast cancer].
Zubrikhina GN; Kuz'mina EV; Bassalyk LS; Murav'eva NI
Vopr Onkol; 1989; 35(10):1179-86. PubMed ID: 2596061
[TBL] [Abstract][Full Text] [Related]
16. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
17. DNA in situ sensitivity to denaturation as a marker of human breast tumors.
Kunicka JE; Olszewski W; Rosen PP; Kimmel M; Melamed MR; Darzynkiewicz Z
Cancer Res; 1989 Nov; 49(22):6347-51. PubMed ID: 2804980
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
19. [The changes in nuclear DNA amounts in the development and progression of uterine cervical cancer determined by cytofluorometry].
Harada K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 May; 38(5):759-68. PubMed ID: 3722955
[TBL] [Abstract][Full Text] [Related]
20. [Assay of DNA content and estrogen receptor status in human breast cancer].
Chen GJ; Shao YF; Shan Y
Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):461-4. PubMed ID: 7720507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
